Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

StudyThe Journal of dermatological treatment· Dec 2026

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

Raj Chovatiya, Matthew Zirwas, Melinda J Gooderham … Gary Chan

Read paper

Inflammatory & ImmunodermatologyStudyTreatmentQ1IF 3.6

Only 12.5% of patients changed abrocitinib dose due to adverse events.

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

Raj Chovatiya … Gary Chan

The Journal of dermatological treatment · Dec 2026 · Q1 in Dermatology

Background

JADE REAL was a global, prospective, multicenter, open-label expanded access protocol study that integrated the rigorous follow-up, safety, and efficacy assessments of a clinical trial with dosing flexibility and ability to use concomitant topical therapies to simulate real-world management of atopic dermatitis (atopic dermatitis).

Purpose

The study aimed to provide access to abrocitinib for patients with moderate-to-severe atopic dermatitis without adequate treatments available.

Methods

Eligible patients received abrocitinib 100 mg or 200 mg once daily per investigator's discretion.

n = 312 patients

Results

adverse effects rarely forced a dose change, so most patients stayed on their starting dose

38.5%

100 mg

61.5%

200 mg

More results

Of 312 patients, 120 (38.5%) and 192 (61.5%) received an initial dose of abrocitinib 100 mg and 200 mg, respectively.

TEAEs were reported in 78.2% of patients.

Rapid improvements in atopic dermatitis severity progressed up to 72 weeks among observed patients.

“

Conclusion · 1 of 2

Most patients continued their initial dose of abrocitinib. TEAEs accounted for a minority of documented dose reductions; instead, investigators may have determined that the patients' disease could be maintained at a lower dose.

Conclusion · 2 of 2

These findings support clinical decision-making around dose selection and modification.

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

Related papers